Clinical bottom line
Liquid biopsy technologies, particularly circulating tumor DNA (ctDNA) assays, are rapidly advancing as promising tools for early cancer detection across multiple tumor types. Current evidence supports their potential to identify malignancies at asymptomatic stages, enabling earlier intervention and personalized management. However, sensitivity varies by cancer type and stage, and challenges remain in distinguishing benign from malignant signals and integrating these assays into clinical workflows. Ongoing validation and standardization efforts are critical before widespread implementation (Xu et al., 2025; Pascual et al., 2022).
What the evidence shows
Xu et al. (2025) provide a comprehensive overview of multi-cancer early detection (MCED) via liquid biopsy, highlighting platforms that analyze ctDNA methylation patterns and fragmentation profiles. Their review demonstrates that MCED tests can detect over 50 cancer types with variable sensitivity, generally higher for advanced stages but improving for early-stage disease. Specificity is typically above 99%, reducing false positives.
Pascual et al. (2022) report European Society for Medical Oncology (ESMO) recommendations endorsing ctDNA assays for molecular profiling and monitoring in established cancers, while emphasizing that early detection applications require further evidence. They stress the importance of assay validation, clinical utility, and cost-effectiveness analyses.
Vandekerckhove et al. (2023) focus on early-stage lung cancer, where liquid biopsy complements imaging by detecting actionable mutations and minimal residual disease. They note that ctDNA detection rates correlate with tumor burden, limiting sensitivity in very early lesions.
Kuhlen et al. (2026) review liquid biopsy in hereditary cancer syndromes, suggesting potential for surveillance and early intervention but cautioning that evidence remains preliminary.
David et al. (2023) discuss gastrointestinal cancers, where liquid biopsy aids early detection and guides individualized treatment, though challenges include tumor heterogeneity and assay standardization.
Mishra et al. (2024) highlight emerging data in gallbladder carcinoma, a rare but aggressive malignancy, where liquid biopsy may improve early diagnosis and prognostication.
Caveats and uncertainty
Sensitivity for early-stage cancers remains suboptimal, risking false negatives.
False positives from clonal hematopoiesis or benign conditions pose diagnostic dilemmas.
Heterogeneity in assay platforms, targets, and bioinformatics complicates standardization.
Clinical utility in screening asymptomatic populations is not yet established.
Cost, accessibility, and integration into existing screening programs require evaluation.
Ethical considerations include patient counseling and management of incidental findings.
How this may change practice
Liquid biopsy could augment or partially replace invasive tissue biopsies and imaging in cancer screening and surveillance.
Integration with risk stratification tools may optimize patient selection for testing.
Early detection via liquid biopsy may enable timely, less invasive treatments and improve outcomes.
Multidisciplinary collaboration is essential to interpret results and guide management.
Health systems should prepare for implementation challenges including infrastructure and reimbursement.
Ongoing trials and real-world studies will clarify clinical pathways and refine guidelines.